x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230606
| Product Information | |
|---|---|
| CAS No. | 1386874-06-1 |
| Chemical Name | 8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methylimidazo[4,5-c]quinolin-2-one |
| Formula | C23H26N4O3 |
| Molecular Weight | 406.50 |
| PubChem CID | 57519748 |
| SMILES | CC(CN1C2=C3C=C(C=CC3=NC=C2N(C1=O)C)C4=CC(=CN=C4)C(C)(C)O)OC |
| Target | PI3K isoforms, mTOR and DNA-PK |
| Product Description | LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK. |
| Format & Storage | |
|---|---|
| Purity | > 98% |
| Source | Synthetic |
| Shipping | Shipped on dry ice. |
| Storage | Store at -20 °C long term. This product is air and light sensitive and impurities can occur as a result of air oxidation or due to metabolism by microbes. |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
